{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:15:08Z","timestamp":1763550908343,"version":"3.45.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["109-N4644","109-P05","110-N4850","110-P06","110-EDN08","111N0067"],"award-info":[{"award-number":["109-N4644","109-P05","110-N4850","110-P06","110-EDN08","111N0067"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST 109-2314-B-002-086","MOST 110-2314-B-002 -040"],"award-info":[{"award-number":["MOST 109-2314-B-002-086","MOST 110-2314-B-002 -040"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00535-025-02306-z","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T04:11:08Z","timestamp":1760155868000},"page":"1572-1583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis B core-related antigen kinetics predict spontaneous HBeAg seroclearance in chronic hepatitis B patients"],"prefix":"10.1007","volume":"60","author":[{"given":"Hung-Yao","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Hui","family":"Hsin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Chin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Jer","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Chih","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"2306_CR1","volume-title":"Global hepatitis report 2024: action for access in low-and middle-income countries","author":"WH Organization","year":"2024","unstructured":"Organization WH. Global hepatitis report 2024: action for access in low-and middle-income countries. World Health Organization; 2024."},{"issue":"1","key":"2306_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12916-017-0820-x","volume":"15","author":"TC Tseng","year":"2017","unstructured":"Tseng TC, Kao JH. Elimination of hepatitis B: is it a mission possible? BMC Med. 2017;15(1):53.","journal-title":"BMC Med"},{"issue":"10","key":"2306_CR3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","volume":"8","author":"D Razavi-Shearer","year":"2023","unstructured":"Razavi-Shearer D, Gamkrelidze I, Pan C, Jia J, Berg T, Gray R, et al. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023;8(10):879\u2013907.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"2306_CR4","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1053\/gast.2002.33588","volume":"122","author":"CJ Chu","year":"2002","unstructured":"Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122(7):1756\u201362.","journal-title":"Gastroenterology"},{"issue":"2","key":"2306_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1053\/j.gastro.2008.10.089","volume":"136","author":"HS Kim","year":"2009","unstructured":"Kim HS, Kim HJ, Shin WG, et al. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2009;136(2):505\u201312.","journal-title":"Gastroenterology"},{"issue":"2","key":"2306_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/hep.23348","volume":"51","author":"YC Chen","year":"2010","unstructured":"Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010;51(2):435\u201344.","journal-title":"Hepatology"},{"issue":"1","key":"2306_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s44263-023-00026-1","volume":"1","author":"CW Spearman","year":"2023","unstructured":"Spearman CW, Andersson MI, Bright B, et al. A new approach to prevent, diagnose, and treat hepatitis B in Africa. BMC Glob Public Health. 2023;1(1):24.","journal-title":"BMC Glob Public Health"},{"issue":"4","key":"2306_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jhep.2022.12.017","volume":"78","author":"C Adraneda","year":"2023","unstructured":"Adraneda C, Tan YC, Yeo EJ, Kew GS, Khakpoor A, Lim SG. A critique and systematic review of the clinical utility of hepatitis B core-related antigen. J Hepatol. 2023;78(4):731\u201341.","journal-title":"J Hepatol"},{"issue":"1","key":"2306_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cgh.2020.04.045","volume":"19","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Desbiolles A, Feldman SF, et al. Hepatitis B core-related antigen to indicate high viral load: systematic review and meta-analysis of 10,397 individual participants. Clin Gastroenterol Hepatol. 2021;19(1):46-60.e48.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2306_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2468-1253(25)00015-9","volume":"10","author":"JP Vincent","year":"2025","unstructured":"Vincent JP, S\u00e9g\u00e9ral O, Kania D, et al. Hepatitis B core-related antigen rapid diagnostic test for point-of-care identification of women at high risk of hepatitis B vertical transmission: a multicountry diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2025;10(5):452\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2306_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1053\/j.gastro.2023.01.005","volume":"164","author":"TC Tseng","year":"2023","unstructured":"Tseng TC, Chiang C, Liu CJ, et al. Low hepatitis B core-related antigen levels correlate higher spontaneous seroclearance of hepatitis B surface antigen in chronic hepatitis B patients with high hepatitis B surface antigen levels. Gastroenterology. 2023;164(4):669-679.e666.","journal-title":"Gastroenterology"},{"issue":"5","key":"2306_CR12","doi-asserted-by":"publisher","first-page":"748","DOI":"10.14309\/ajg.0000000000001691","volume":"117","author":"TC Tseng","year":"2022","unstructured":"Tseng TC, Hosaka T, Liu CJ, et al. Hepatitis B core-related antigen stratifies the risk of liver cancer in HBeAg-negative patients with indeterminate phase. Am J Gastroenterol. 2022;117(5):748\u201357.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2306_CR13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/liv.13046","volume":"36","author":"N Chuaypen","year":"2016","unstructured":"Chuaypen N, Posuwan N, Payungporn S, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int. 2016;36(6):827\u201336.","journal-title":"Liver Int"},{"issue":"7","key":"2306_CR14","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/j.cgh.2022.06.019","volume":"21","author":"WC King","year":"2023","unstructured":"King WC, Sterling RK, Hinerman AS, Lok ASF, Cloherty GA, Ghany MG. Hepatitis B RNA and core-related antigen provide value beyond DNA in evaluating e but not surface antigen clearance. Clin Gastroenterol Hepatol. 2023;21(7):1957\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"2306_CR15","doi-asserted-by":"publisher","first-page":"E172","DOI":"10.1111\/hepr.12287","volume":"44","author":"S Okuhara","year":"2014","unstructured":"Okuhara S, Umemura T, Joshita S, et al. Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatol Res. 2014;44(10):E172-180.","journal-title":"Hepatol Res"},{"issue":"3","key":"2306_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jmv.24657","volume":"89","author":"G Song","year":"2017","unstructured":"Song G, Yang R, Rao H, et al. Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients. J Med Virol. 2017;89(3):463\u20138.","journal-title":"J Med Virol"},{"issue":"6","key":"2306_CR17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1053\/j.gastro.2019.08.028","volume":"157","author":"TC Tseng","year":"2019","unstructured":"Tseng TC, Liu CJ, Hsu CY, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology. 2019;157(6):1518\u201329.","journal-title":"Gastroenterology"},{"issue":"10","key":"2306_CR18","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/ajg.2017.254","volume":"112","author":"TC Tseng","year":"2017","unstructured":"Tseng TC, Liu CJ, Su TH, et al. Fibrosis-4 index helps identify HBV carriers with the lowest risk of hepatocellular carcinoma. Am J Gastroenterol. 2017;112(10):1564\u201374.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2306_CR19","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","volume":"142","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142(5):1140\u20139.","journal-title":"Gastroenterology"},{"issue":"8","key":"2306_CR20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/apt.16266","volume":"53","author":"TC Tseng","year":"2021","unstructured":"Tseng TC, Liu CJ, Yang WT, et al. Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Aliment Pharmacol Ther. 2021;53(8):908\u201318.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2306_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/hep.26041","volume":"57","author":"TC Tseng","year":"2013","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57(2):441\u201350.","journal-title":"Hepatology"},{"issue":"2","key":"2306_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","volume":"141","author":"TC Tseng","year":"2011","unstructured":"Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141(2):517\u201325.","journal-title":"Gastroenterology"},{"issue":"4","key":"2306_CR23","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"3","key":"2306_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020\u20132.","journal-title":"Hepatology"},{"issue":"4","key":"2306_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2004.06.031","volume":"41","author":"SH Yeh","year":"2004","unstructured":"Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol. 2004;41(4):659\u201366.","journal-title":"J Hepatol"},{"issue":"10","key":"2306_CR26","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/sim.4154","volume":"30","author":"H Uno","year":"2011","unstructured":"Uno H, Cai T, Pencina MJ, D\u2019Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30(10):1105\u201317.","journal-title":"Stat Med"},{"issue":"5","key":"2306_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","volume":"11","author":"MA Hern\u00e1n","year":"2000","unstructured":"Hern\u00e1n MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561\u201370.","journal-title":"Epidemiology"},{"issue":"1","key":"2306_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65\u201373.","journal-title":"JAMA"},{"issue":"10","key":"2306_CR29","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","volume":"28","author":"VW Wong","year":"2010","unstructured":"Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660\u20135.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2306_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","volume":"50","author":"MF Yuen","year":"2009","unstructured":"Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50(1):80\u20138.","journal-title":"J Hepatol"},{"issue":"14","key":"2306_CR31","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.2009.27.4456","volume":"28","author":"HI Yang","year":"2010","unstructured":"Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28(14):2437\u201344.","journal-title":"J Clin Oncol"},{"key":"2306_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001313","author":"TC Tseng","year":"2025","unstructured":"Tseng TC, Hosaka T, Pan MH, et al. Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients. Hepatology. 2025. https:\/\/doi.org\/10.1097\/hep.0000000000001313.","journal-title":"Hepatology"},{"issue":"5","key":"2306_CR33","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1097\/HEP.0000000000000413","volume":"78","author":"MG Ghany","year":"2023","unstructured":"Ghany MG, King WC, Hinerman AS, et al. Use of HBV RNA and hepatitis B core-related antigen to predict change in serological status and disease activity in CHB. Hepatology. 2023;78(5):1542\u201357.","journal-title":"Hepatology"},{"issue":"5","key":"2306_CR34","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1002\/hep.32018","volume":"74","author":"MG Ghany","year":"2021","unstructured":"Ghany MG, King WC, Lisker-Melman M, et al. Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in north America. Hepatology. 2021;74(5):2395\u2013409.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02306-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02306-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02306-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:14:10Z","timestamp":1763550850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02306-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2306"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02306-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T-C. T. has served on speakers\u2019 bureaus for Fujirebio, Roche, AstraZeneca, and Gilead Sciences and has received grant support from Gilead Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}